The new injectable drug lenacapavir provides a promising 100% protection against HIV infection in teenage girls and women in Africa, as highlighted by Science magazine as a significant achievement for 2024. With injections providing six months of protection, the drug targets a key protein of the HIV virus, potentially paving the way for treatments of other viral diseases. However, global success hinges on affordability and healthcare infrastructure, with regulatory approval expected by 2025.

Source